Department of Radiology, Mayo Medical School and Clinic, 200 First Street SW, Rochester, MN 55905, USA.
AJNR Am J Neuroradiol. 2010 Oct;31(9):1631-4. doi: 10.3174/ajnr.A2145. Epub 2010 Jun 3.
INVEST is a recently published double-blind placebo controlled randomized trial that demonstrated similar improvements in pain between blinded vertebroplasty and sham-vertebroplasty groups. LABEL is a trial determining the efficacy of pain relief of an injection of lidocaine and bupivacaine at the site of painful osteoporotic vertebral compression fractures in unblinded patients. We compared outcomes from the unblinded LABEL trial with those of blinded control patients from the lead site of the INVEST, exploring the role of blinding on the benefit of local anesthesia infusion for painful vertebral compression fractures.
Nineteen patients with painful osteoporotic vertebral compression fractures underwent unblinded injection of lidocaine and bupivacaine at the site of painful osteoporotic vertebral compression fractures. Patients were given the option of undergoing vertebroplasty at any time following the procedure. Primary outcome measures were change in the RDQ and pain (at rest, with activity, and average 24-hour pain) at days 1 and 3 following the injection. Day 3 change in RDQ scores and change in average 24-hour pain were compared for LABEL and INVEST control patients from the lead site (n = 16).
Among patients in the LABEL trial, we detected no significant improvement in RDQ scores, pain at rest, and average 24-hour pain at days 1 and 3, whereas pain with activity improved significantly at both time points. INVEST control patients from the lead site experienced significantly greater improvement in average pain during 24 hours at days 1 (P = .03) and 3 (P = .04) and significantly greater improvements in RDQ scores at day 3 (P = .006) than patients from LABEL.
An unblinded injection of local anesthesia is ineffective in treating pain from osteoporotic compression fractures. This suggests that factors other than local anesthesia were responsible for the observed improvement in the control group in INVEST.
INVEST 是最近发表的一项双盲安慰剂对照随机试验,结果表明,接受盲法椎体成形术和假手术椎体成形术的患者疼痛均有相似程度的改善。LABEL 是一项旨在确定在未盲患者中,于疼痛性骨质疏松性椎体压缩性骨折部位注射利多卡因和布比卡因的镇痛效果的试验。我们比较了来自 INVEST 主导中心的盲法对照患者和未盲 LABEL 试验患者的结局,旨在探讨盲法对局部麻醉浸润治疗疼痛性椎体压缩性骨折获益的影响。
19 例疼痛性骨质疏松性椎体压缩性骨折患者接受了疼痛性骨质疏松性椎体压缩性骨折部位的未盲利多卡因和布比卡因注射。患者在该操作后可随时选择行椎体成形术。主要结局测量指标为注射后第 1 天和第 3 天的 RDQ 变化和疼痛(静息时、活动时和平均 24 小时疼痛)。比较 LABEL 和 INVEST 主导中心的对照患者(n=16)的第 3 天 RDQ 评分变化和平均 24 小时疼痛变化。
在 LABEL 试验中,我们发现 RDQ 评分、静息时疼痛和平均 24 小时疼痛均无显著改善,而活动时疼痛在两个时间点均显著改善。INVEST 主导中心的对照患者在第 1 天(P=0.03)和第 3 天(P=0.04)的 24 小时平均疼痛和第 3 天的 RDQ 评分均有显著改善(P=0.006),而 LABEL 患者则无显著改善。
未盲注射局部麻醉对治疗骨质疏松性压缩性骨折疼痛无效。这表明,在 INVEST 中对照组观察到的改善并非由局部麻醉以外的因素所致。